Company / Shareholders' Equity
Edwards Lifesciences Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$10.3B
FY2025
5-year range
$5.8B / $10.3B
FY2021-FY2025
Trend
+3.4%
vs FY2024
Sector context
#17 of 161
Health Care
What the data says
Edwards Lifesciences's shareholders' equity of $10.3B is higher than 89% of companies in the Health Care sector (FY2025). Shareholders' Equity has increased for 3 consecutive years, from $5.8B in FY2022 to $10.3B in FY2025.
Based on SEC 10-K filings.
$10.3B in FY2025 with a 5-year CAGR of +17.7%. Top quartile in the Health Care sector.
Improved from $6.7B to $10.3B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +21.2%
- 5-Year CAGR
- +17.7%
- 10-Year CAGR
- -
Sector benchmark
+104.2% above sector average
Key checks
Key Insights
- Edwards Lifesciences's shareholders' equity has grown for 3 consecutive years.
- 5-year CAGR of +17.7%, indicating consistent growth.
- In FY2025, shareholders' equity increased 3.4% year-over-year.
- Ranks #17 out of 161 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.3B | +3.4% |
| FY2024 | $10.0B | +50.4% |
| FY2023 | $6.7B | +14.5% |
| FY2022 | $5.8B | -0.5% |
| FY2021 | $5.8B | +27.6% |
| FY2020 | $4.6B | +10.3% |
| FY2019 | $4.1B | +32.1% |
| FY2018 | $3.1B | +6.2% |
| FY2017 | $3.0B | +12.9% |
| FY2016 | $2.6B | +4.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026